Prostate Biopsy Complications Deter Patients From Re-Biopsy
Of 4939 men (aged 50 to 75 years) who underwent prostate biopsy at 2 years in the REDUCE trial, 5.3% experienced a complication such as hematuria, urinary tract infection (UTI), acute urinary retention (AUR), or hematospermia. In multivariable analysis, having any complication was associated with significant 65% greater odds of avoiding recommended re-biopsy at 4 years. Previous biopsy-related AUR, UTI, and hematospermia were associated with significant 4.5, 2.6, and 1.8 times greater odds of noncompliance, respectively. Results were hematuria were not significant.
In men undergoing repeat prostate biopsy, a previous biopsy-related complication and the type of complication were associated with lower compliance with re-biopsy schemes. Patients experiencing biopsy-related complications are ideal candidates to receive interventions regarding the importance of prostate re-biopsy to prevent noncompliance. The investigators suggested urologists explain how the benefits of re-biopsy outweigh the risks.